Nuvilex (NASDAQ:PMCB) Trading Up 5.3% – What’s Next?

Shares of Nuvilex Inc. (NASDAQ:PMCB) were up 5.3% during mid-day trading on Monday . The stock traded as high as $0.6949 and last traded at $0.6879. Approximately 85,294 shares traded hands during trading, a decline of 45% from the average daily volume of 154,335 shares. The stock had previously closed at $0.6531.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on PMCB shares. Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Thursday, January 22nd. Wall Street Zen upgraded Nuvilex to a “sell” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Nuvilex Stock Performance

The firm has a market capitalization of $8.37 million, a P/E ratio of -0.70 and a beta of 0.41. The stock has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.82.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.